ApicHope Pharmaceutical (SHE:300723) received clinical trial approval from China's National Medical Products Administration for its self-developed APH04935 tablets for weight control.
The tablets are a selective small-molecule GLP-1R agonist that promotes insulin secretion and inhibits glucagon through the pancreas, and suppresses appetite, according to a Tuesday filing with the Shenzhen bourse.